Pulmonary Sarcoidosis is a chronic inflammatory pulmonary disease with an unknown etiology, more frequent between 20-50 years of age and in women. The most prominent signs of Pulmonary Sarcoidosis are cough and progressive dyspnea related to the decrease in lung capacity. In some patients, the progression is faster and can lead to death from respiratory failure. Until now, no cure is known and the todays treatment options are only relieving the related symptoms.
With the leadership of Centurion Pharma, a Phase III trial has been started targeting this incurable disease. It is aimed to stop the progression of the disease by the application of a natural protein directly to the respiratory airway. If the results are positive, it will not only be the only approved curative treatment option globally, also the first local developed and patent protected product of Turkey. Animal studies and Phase I trials have presented the efficacy and after completion of the Phase III study, global Registration and marketing in 2020 is planned.
A Phase I study has been planned to start in 2018.
A Phase I study has been planned to start at the begin of 2019.
A Phase I study has been planned to start in 2019.
Phase III trials will start with incurable different diseases including Myasthenia Gravis and Systemic Lupus Erythematosus in 2019.